Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

DOI Full Paper Access

53

Citations

16

References

2020

Year

Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip R. Mallinder, Nairouz Elgeioushi,

Clinical Cancer Research

Abstract

MEDI1873 showed acceptable safety up to 500 mg i.v. every 2 weeks with pharmacodynamics activity, and prolonged SD in some patients. However, further development is not planned because of lack of demonstrated tumor response.

References

	Year	Citations
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation Adam D. Cohen, David Schaer, Cailian Liu, PLoS ONE	2010	255
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity Adam D. Cohen, Adi Diab, Miguel‐Angel Perales, Cancer Research	2006	203
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs Lei Lü, Xiaobing Xu, Bin Zhang, Journal of Translational Medicine	2014	172
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy David Coe, Shaima Begom, Caroline Addey, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceMedicineT-regulatory CellImmunologyPathology	2010	167
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals Jun Mitsui, Hiroyoshi Nishikawa, Daisuke Muraoka, Clinical Cancer Research	2010	136
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors Kimberley M. Heinhuis, Matteo S. Carlino, Markus Joerger, JAMA Oncology	2019	90
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors Ben Tran, Richard D. Carvajal, Aurélien Marabelle, Journal for ImmunoTherapy of Cancer	2018	81
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells Selvakumar Sukumar, Douglas C. Wilson, Ying Yu, Cancer Research	2017	63
GITR ligand-costimulation activates effector and regulatory functions of CD4+ T cells Hanna Igarashi, Yujia Cao, Hideyuki Iwai, Biochemical and Biophysical Research Communications Regulatory FunctionsSignal TransductionT-regulatory CellImmunologyAutoimmunity	2008	47
Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted Young H. Kim, Su M. Shin, Beom K. Choi, The Journal of Immunology	2015	45

Page 1